The aberrant expression of non-coding RNA in both PKD1 and PKD2 patients provides new insight into the pathogenesis of ADPKD and represents promising biomarkers that can improve diagnostic performance and the evaluation of disease progression, as well as acting as a potential therapeutic target. The gene discussed is PKD1; the disease is autosomal dominant polycystic kidney disease.